

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 840 601 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
24.10.2001 Bulletin 2001/43

(51) Int Cl.⁷: **A61K 31/00**, A61K 31/165,
A61K 31/42, A61K 31/435,
A61K 31/44, A61K 31/445

(21) Application number: **96925704.7**

(86) International application number:
PCT/EP96/03018

(22) Date of filing: **10.07.1996**

(87) International publication number:
WO 97/02813 (30.01.1997 Gazette 1997/06)

(54) **THIP FOR TREATING SLEEP DISORDERS**

THIP ZUR BEHANDLUNG VON SCHLAFSTÖRUNGEN

THIP POUR TRAITER DES TROUBLES DU SOMMEIL

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(74) Representative: **VOSSIUS & PARTNER**
Postfach 86 07 67
81634 München (DE)

(30) Priority: **13.07.1995 DE 19525598**

(56) References cited:
WO-A-93/18762 **US-A- 5 192 550**
US-A- 5 354 760

(43) Date of publication of application:
13.05.1998 Bulletin 1998/20

(60) Divisional application:
98102355.9 / 0 867 178
98102356.7 / 0 867 184

- **NEUROPSYCHOPHARMACOLOGY**, vol. 15, no. 1, 1996, pages 63-74, XP000609465 **M. LANCEL ET AL.**: "Role of GABA_A receptors in sleep regulation: differential effects of muscimol and midazolam on sleep in rats."
- **CRIT. REV. NEUROBIOL.**, vol. 6, no. 4, 1992, pages 221-232, XP000609466 **W.B. MENDELSON**: "Neuropharmacology of sleep induction by benzodiazepines."

(73) Proprietor: **Max-Planck-Gesellschaft zur
Förderung der Wissenschaften e.V.**
Berlin (DE)

(72) Inventor: **LANCEL, Marike**
D-80804 Munich (DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 840 601 B1

DescriptionField of the invention

[0001] This invention relates to the use of THIP for the preparation of a pharmaceutical composition for treating sleep disorders.

Background

[0002] The hypnotics most frequently prescribed for the treatment of sleep disorders are classic benzodiazepines as well as compounds like zolpidem and zopiclone. These compounds shorten sleep latency and increase total sleep time. The pharmacological effect of these compounds is assumed to be due to a modulation of the GABA_A receptor (γ -aminobutyric-acid_A receptor); however they neither increase neuronal release of GABA nor block the reuptake of released GABA. They have no direct GABA_A agonistic effect either. On the contrary, they react with specific binding sites which belong to a complex consisting of GABA receptors, various distinct modulatory receptors among others for benzodiazepines and a chloride ion channel, and thus cause the GABA_A receptor to undergo an allosteric change. This allosteric change influences the efficacy of GABA in promoting chloride channel opening.

[0003] However, such GABA_A receptor modulators exhibit considerable side effects. Especially with the use of benzodiazepines, tolerance and dependency develop rapidly, and rebound insomnia, which will manifest itself by restlessness and somniphathy, emerges upon withdrawal.

[0004] Furthermore, the quality of sleep induced by said GABA_A receptor modulators is unphysiological. REMS (= rapid eye movement sleep) as well as the deeper phases of nonREMS (slow-wave sleep) are disturbed.

[0005] For example, benzodiazepines and all other common hypnotics cause the following sleep profile.

1) they inhibit REMS

2) they promote nonREMS

3) they decrease delta activity (0.5-4 Hz) in the EEG within nonREMS by

a) reducing the rate of rise of delta activity at the beginning the nonREMS episodes, and

b) reducing the maximum delta activity during nonREMS episodes.

[0006] In one of two studies, Mendelson et al. (Life Sci 47, (1990) 99, 101; Life Sci 53 (1993) 81-87) found that muscimol, a GABA analogue and selective GABA_A agonist, does cause a slight reduction of sleep latency but does not influence sleep as such. This finding resulted in the common opinion that non-benzodiazepoid GABA_A agonists are devoid of any clinical beneficial effects on sleep disorders. Furthermore, it is generally accepted in the field that if a substance has a sedative side effect or causes a slight reduction in sleep latency, this will not justify its classification as a hypnotic.

[0007] In Pharmacol. Biochem. and Behaviour (1993), vol 45, pp 881-887, Suzuki et al investigated the effect of 3 mg/kg muscimol IP in different inbred strains of rats (Fischer 344, and Lewis) by measuring the loss and duration of the righting reflex. The authors of this document equate the duration of loss of the righting reflex to an hypnotic effect (sleep time). However, it is well established that the behavioral parameter "righting reflex" bears no relationship with sleep. In the rat, very high doses of muscimol, such as 3 mg/kg, are known to evoke absence epilepsy. It is in fact highly likely that the perceived sedation ("loss of righting reflex") represents a pathological state of an epileptiform nature (see "Hypersynchronisation and Sedation Produced by GABA-Transaminase Inhibitors and picrotoxin: Does GABA Participate in Sleep Control?", Waking and Sleeping (1979), 3: 245-254).

[0008] In US-A-5,185,446 cycloalkylidazo pyrimidine derivatives are disclosed which are described as being selective agonists, antagonists or inverse agonists for GABA_a brain receptors and may be used in the diagnosis and treatment of anxiety, sleep and other disorders. All of these compounds are, however, allosteric GABA_a-receptor modulators. In Pharmacol. Biochem. and Behaviour (1988), vol 29, pp 781-783, the hypnotic effects of the allosteric GABA_a-receptor modulators are described.

[0009] The object underlying the present invention is to provide an effective hypnotic which has no significant side effects and causes a sleep profile essentially corresponding to physiological sleep.

Summary of the invention

[0010] The present invention provides the use of THIP for the preparation of a pharmaceutical composition for treating sleep disorders in a patient in need thereof.

Detailed description of the invention

[0011] The present invention is based on the unexpected finding that the full GABA_A agonist muscimol and the partial GABA_A agonist THIP (4,5,6,7-tetrahydroisoxazolo(5,4-C)pyridin-3-ol) have very advantageous effects on sleep. The activity profiles of muscimol- and THIP-induced sleep can be summarized as follows:

- 1) The total duration of nonREMS and REMS is increased after muscimol and THIP increases nonREMS.
- 2) Prolongation of nonREMS episodes as well as REMS episodes, which supports sleep continuity.
- 3) The EEG-delta activity within nonREMS is enhanced; this is achieved by
 - a) increasing the rise rate of delta activity at the beginning of each nonREMS episode,
 - b) increasing the maximum delta activity during the nonREMS episodes, and
 - c) prolonging the nonREMS episodes (see 2).

[0012] All above-summarized changes correspond to the sleep profile observed with a physiological increase in sleep need, for instance, after an extended period of wakefulness. This shows that muscimol and THIP, unlike benzo-diadepines and all other common hypnotics, can induce sleep having the characteristics of natural sleep.

[0013] The use of THIP as partial agonist is preferred since it does not result in a rapid desensitisation of the GABA_A receptor.

[0014] Thus, the invention relates to the use of THIP for the preparation of a medicament for treating sleep disorders in a patient in need thereof.

[0015] Due to its pharmacological properties, THIP having a direct non-allosteric agonistic effect on the GABA_A receptor is therapeutically beneficial in a broad range of sleep disorders, including difficulties in falling asleep, frequent nocturnal arousals, early morning awakening and/or a dissatisfaction with the intensity of sleep.

[0016] THIP is particularly suitable for the treatment of elderly patients.

[0017] THIP can be formulated in a manner well-known in the art using common pharmaceutical adjuvants and optionally in combination with other active substances to form common galenic preparations, such as tablets, coated tablets, capsules, powders, suspensions, injectable solutions or suppositories.

In accordance with the subject matter of the invention, the compounds can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, the compounds can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances.

[0018] THIP can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and chemical properties of the compound selected, the chosen route of administration, and standard pharmaceutical practice. THIP, while effective itself, may be formulated and administered in the form of its pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.

[0019] The dose to be administered depends on the patient's age and weight as well as the degree and nature of sleep disorder. Preferably, THIP is administered in a dose of 5 mg to 50 mg per day. The administration may be intravenous or intramuscular. However, oral administration is preferred.

[0020] As used herein, the term "hypnotically effective amount" means an amount sufficient to reduce sleep latency, prolong REMS, prolong nonREMS, prolong total sleep or enhance EEG-delta activity during sleep.

[0021] The following examples serve to explain the invention in more detail. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way.

Example 1

[0022] After intraperitoneal administration of Placebo (pyrogen-free saline) or THIP (2 and 4 mg/kg), the EEG and EMG as well as the brain temperature of adult rats were continuously recorded.

[0023] THIP dose-dependently increased the total amount of nonREMS and lengthened the duration of the nonREMS and REMS episodes. The higher dose of THIP elevated delta activity within nonREMS, generally believed to reflect an increase in nonREMS intensity.

Example 2

[0024] In a double blind, placebo controlled study the effects of 20 mg THIP administered in gelatine capsules at 22:30 h on sleep in 10 young, healthy male subjects was investigated. The subjects went to bed at 23:00 h and time in bed was not restricted. Compared to the placebo condition, THIP significantly increased sleep efficiency and enhanced total time spent in slow wave sleep (stages 3 and 4) by about 30 minutes. Spectral analysis of the EEG within nonREMS (stages 2, 3 and 4) showed that THIP significantly elevated delta activity (cumulative power in the frequency bins between 0.78 and 4.30 Hz) and depressed sigma activity (cumulative power in the frequency bins between 12.50 and 14.83 Hz, the spindle frequency bands). Analysis of the development of delta and sigma activity over the first 30 minutes of the nonREMS episodes revealed that during THIP delta activity increased more rapidly and reached higher levels, while sigma activity remained below placebo values. These effects are highly similar to those induced by sleep deprivation in humans.

[0025] The effects of THIP on sleep in young human subjects, with no sleep disturbances, confirm and extend the findings of GABA_A agonists in rats and show that THIP, similar to sleep deprivation and in contrast to existing hypnotics, promotes deep nonREMS, without suppressing REMS.

Example 3

[0026]

Coated tablets:		
1	tablet contains:	
	THIP	40.00 mg
	microcrystalline cellulose	100.00 mg
	lactose	80.00 mg
	colloidal silicic acid	25.00 mg
	talcum (in the core)	4.50 mg
	magnesium stearate	0.50 mg
	hydroxypropylmethylcellulose	12.00 mg
	ironoxide pigment	0.10 mg
	talcum (in the coating)	0.50 mg
	weight of one coated tablet	approx. 262.60 mg

Claims

1. Use of THIP for the preparation of a pharmaceutical composition for treating a sleep disorder.
2. Use according to claim 1 for the treatment of an elderly patient.
3. Use according to claim 1, wherein said sleep disorder is difficulty in falling asleep.
4. Use according to claim 1, wherein said sleep disorder is frequent nocturnal arousal.
5. Use according to claim 1, wherein the amount of THIP administered is 5 to 50 mg per day.

Patentansprüche

1. Verwendung von THIP zur Herstellung eines Arzneimittels zur Behandlung einer Schlafstörung.
- 5 2. Verwendung nach Anspruch 1 zur Behandlung eines älteren Patienten.
3. Verwendung nach Anspruch 1, wobei die Schlafstörung in Einschlafschwierigkeiten besteht.
4. Verwendung nach Anspruch 1, wobei die Schlafstörung häufiges nächtliches Aufwachen ist.
- 10 5. Verwendung nach Anspruch 1, wobei die verabreichte Menge von THIP 5 bis 50 mg pro Tag ist.

Revendications

- 15 1. Utilisation de THIP pour la préparation d'une composition pharmaceutique destinée au traitement d'un trouble du sommeil.
2. Utilisation selon la revendication 1 pour le traitement d'un patient âgé.
- 20 3. Utilisation selon la revendication 1, dans laquelle ledit trouble du sommeil est la difficulté de s'endormir.
4. Utilisation selon la revendication 1, dans laquelle ledit trouble du sommeil est le réveil nocturne fréquent.
- 25 5. Utilisation selon la revendication 1, dans laquelle la quantité de THIP administré est de 5 à 50 mg/jour.